AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Frequently asked questions
What sector does AgomAb Therapeutics NV American Depositary Shares (AGMB) operate in?
AgomAb Therapeutics NV American Depositary Shares belongs to the Healthcare sector and operates in the Biotechnology industry.
What is AgomAb Therapeutics NV American Depositary Shares (AGMB) current stock price?
As of the latest data, AgomAb Therapeutics NV American Depositary Shares stock price is $13.69, with a previous close of $13.22. AgomAb Therapeutics NV American Depositary Shares gained $0.47 in the last trading session, representing a 3.56% increase.
What is AgomAb Therapeutics NV American Depositary Shares (AGMB) current market capitalization?
AgomAb Therapeutics NV American Depositary Shares market cap is approximately 674.20 million.
What is AgomAb Therapeutics NV American Depositary Shares (AGMB) Earnings Per Share (EPS)?
The trailing EPS is -$1.62, and the forward EPS is -$2.11.
What is AgomAb Therapeutics NV American Depositary Shares (AGMB) EBITDA?
AgomAb Therapeutics NV American Depositary Shares EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.80 million.
Does AgomAb Therapeutics NV American Depositary Shares (AGMB) pay dividends?
No. AgomAb Therapeutics NV American Depositary Shares does not pay a dividend.
When is AgomAb Therapeutics NV American Depositary Shares (AGMB) next earnings report?
AgomAb Therapeutics NV American Depositary Shares is expected to release its next earnings report on June 30, 2026.
What is AgomAb Therapeutics NV American Depositary Shares (AGMB) beta (volatility) score?
AgomAb Therapeutics NV American Depositary Shares has a beta of 0.088, indicating lower volatility than the overall market.
